ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 621,079 shares of the biotechnology company’s stock after buying an additional 5,881 shares during the quarter. Rhumbline Advisers’ holdings in ADMA Biologics were worth $10,651,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. New York State Teachers Retirement System lifted its position in ADMA Biologics by 24.1% in the 4th quarter. New York State Teachers Retirement System now owns 113,090 shares of the biotechnology company’s stock valued at $1,939,000 after purchasing an additional 21,976 shares during the last quarter. Van ECK Associates Corp bought a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $3,424,000. Allspring Global Investments Holdings LLC boosted its position in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares during the period. Louisiana State Employees Retirement System grew its holdings in ADMA Biologics by 1.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 114,300 shares of the biotechnology company’s stock worth $1,960,000 after buying an additional 1,600 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in ADMA Biologics in the 4th quarter valued at approximately $5,680,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $15.84 on Monday. The stock has a market cap of $3.74 billion, a price-to-earnings ratio of 56.57 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 12 month low of $5.08 and a 12 month high of $23.64. The stock’s 50 day moving average price is $16.97 and its 200 day moving average price is $18.00.

Analyst Ratings Changes

Several brokerages have weighed in on ADMA. HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.